IceCure Medical Ltd (NASDAQ:ICCM - Get Free Report) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 598,100 shares, a decline of 22.7% from the February 13th total of 773,300 shares. Based on an average trading volume of 385,300 shares, the short-interest ratio is currently 1.6 days. Approximately 2.1% of the company's shares are short sold.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and set a $2.50 target price on shares of IceCure Medical in a report on Wednesday, November 27th.
View Our Latest Stock Report on ICCM
IceCure Medical Stock Performance
Shares of NASDAQ:ICCM traded down $0.01 during trading on Friday, reaching $1.24. 152,676 shares of the company's stock traded hands, compared to its average volume of 513,424. The company has a 50 day moving average of $1.32 and a 200-day moving average of $0.97. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.27. The stock has a market capitalization of $68.82 million, a P/E ratio of -4.26 and a beta of 0.37. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.66.
Institutional Inflows and Outflows
An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC boosted its holdings in shares of IceCure Medical Ltd (NASDAQ:ICCM - Free Report) by 58.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,453 shares of the company's stock after purchasing an additional 14,893 shares during the period. Geode Capital Management LLC owned approximately 0.07% of IceCure Medical worth $44,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.62% of the company's stock.
IceCure Medical Company Profile
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Featured Stories
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
